This company listing is no longer active
6I7 Stock Overview
Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Labomar S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.45 |
| 52 Week High | €9.95 |
| 52 Week Low | €7.38 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | -3.08% |
| 1 Year Change | 13.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6I7 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | -1.3% |
| 1Y | 13.6% | -3.2% | 4.1% |
Return vs Industry: 6I7 exceeded the German Personal Products industry which returned 12.1% over the past year.
Return vs Market: 6I7 exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| 6I7 volatility | |
|---|---|
| 6I7 Average Weekly Movement | 1.5% |
| Personal Products Industry Average Movement | 4.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6I7 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6I7's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 355 | Walter Bertin | https://labomar.com |
Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally. It offers food supplements for various therapeutic areas, including immune systems, gastroenterology, cough and cold, neurology, oncology, eyesight wellness, sport, dermatology, inside beauty, cardiology, orthopedics, pediatrics, detoxing, and metabolic syndrome; and vitamins, minerals, and antioxidants. The company also provides medical devices for the use in gynaecology, cough and cold, gastroenterology, wound healing, metabolic syndrome, proctology, detoxing, and oral wound care therapeutic areas; and foods for special medical purposes, such as gastroenterology, endocrinology, and dysphagia.
Labomar S.p.A. Fundamentals Summary
| 6I7 fundamental statistics | |
|---|---|
| Market cap | €183.92m |
| Earnings (TTM) | €6.14m |
| Revenue (TTM) | €92.98m |
29.9x
P/E Ratio2.0x
P/S RatioIs 6I7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6I7 income statement (TTM) | |
|---|---|
| Revenue | €92.98m |
| Cost of Revenue | €56.53m |
| Gross Profit | €36.44m |
| Other Expenses | €30.30m |
| Earnings | €6.14m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 39.20% |
| Net Profit Margin | 6.61% |
| Debt/Equity Ratio | 73.1% |
How did 6I7 perform over the long term?
See historical performance and comparison